News Releases

News & Events

News Releases

Synteract Honored with Four Life Science Leader 2015 CRO Leadership Awards

International CRO recognized for providing consistent, high-quality services to emerging biopharma companies

SAN DIEGO – May 11, 2015 – Synteract, a full-service, international contract research organization (CRO), is the recipient of four 2015 CRO Leadership Awards from Life Science Leader magazine. Based on industry-leading research conducted by Nice Insight, the awards highlight leading CROs that achieve top 10 percentile perception scores in the areas of innovation, productivity, quality, regulatory, and reliability as ranked by pharmaceutical and biopharmaceutical companies using CRO services. 

Life Science Leader divided the research respondents into five categories: big pharma, mid-sized and specialty pharma, emerging pharma, biotech, and emerging biotech. It then looked at the top scores in each perception category (quality, productivity, reliability, innovation, and regulatory) by company type. The top 10% plus ties in each of these categories were chosen as winners of a CRO Leadership Award.

Synteract won in the following groups:

  • Innovation - Emerging Pharma: Business will enhance in-house capabilities through a new idea, method or device
  • Reliability - Emerging Pharma: Business will meet all project milestones and timelines
  • Productivity - Emerging Pharma: Business will deliver on agreed objectives
  • Regulatory - Emerging Pharma: Business is reputable and compliant 

"We are honored to receive these awards determined by senior executives in the pharmaceutical and biopharmaceutical industry," said Wendel Barr, chief executive officer at Synteract. "Our international team has more than two decades of experience managing the clinical development process for emerging and midsized biopharma companies. Our ‘Shared Work – Shared Vision’ philosophy exemplifies the custom planning and collaborative support we deliver to help them through each critical phase of their clinical research programs.  As a result, we are proud to know we bring tomorrow’s treatments to patients who need them.”

For more information about Synteract's services for emerging pharmaceutical and biopharmaceutical companies, click here

About Synteract                                                     
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies. Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, Synteract provides customized services collaboratively and cost effectively to provide “Tomorrow’s Treatments” to the patients who need them.


Amanda Whitlock


Contact Synteract

Tell us how to stay in touch with you: